Tirzepatide vs. Retatrutide: One Is Approved, One Is Not

Short answer: tirzepatide is FDA-approved (as Zepbound and Mounjaro). Retatrutide, an experimental Eli Lilly medicine that targets three hormone receptors, was still investigational as of September 2026 and is not FDA-approved. Retatrutide sold online as a supplement or research peptide is unapproved and unverified.

What each one is

• Tirzepatide: approved, once-weekly, activates GLP-1 and GIP receptors.
• Retatrutide: investigational, once-weekly injection in Phase 3 trials, designed to activate GLP-1, GIP, and glucagon receptors.

Where retatrutide stands

Retatrutide is being studied in a large Phase 3 program for obesity and related conditions. A drug is not approved until the FDA reviews the complete evidence, which had not happened when this page was last updated. Trial results reported so far apply only to people taking the study drug under research conditions, and they are not a basis for our calculator's estimates. Status can change, so check the FDA and the manufacturer for current information.

The risk of buying it online

Because interest is high, many websites sell "retatrutide" as a research peptide, often labeled "not for human consumption." These products are not approved, are not made under FDA oversight, and cannot be verified for what is actually in the vial or at what dose. Injecting them means taking on unknown purity, dosing, and safety risks with no medical supervision.

What to do instead

If you want a medication for weight management today, the approved options are the ones a licensed provider can prescribe. Some investigational drugs are available through supervised clinical trials or expanded-access programs, and your provider can advise on those.